Abstract 1588P
Background
HZ infection is a potential cause of additional morbidity in immunocompromised patients (pts). ASCO, ESMO, and AIOM recommend recombinant zoster vaccine (RZV, Shingrix®, GSK) for pts who are immunocompromised due to cancer therapy. Vaccination rates among these pts remain suboptimal, and research on effective interventions to improve vaccination rates is limited. We report quality improvement interventions aimed at enhancing vaccine uptake among cancer outpatients.
Methods
A two-phase vaccination program for cancer outpatients receiving cancer treatments attending the Medical Oncology department of ASST Rhodense was conducted. Firstly, based on previous COVID-19 experience and with the collaboration of pts asociation La Lampada di Aladino ETS, a cross-sectional survey was administered to evaluate knowledge and awareness about HZ and RZV, vaccine hesitancy and the willingness of oncology pts to receive the RZV directly in the oncology department. Subsequently, an in-house vaccination program was managed by oncology staff.
Results
Two hundred pts conducted the survey while undergoing cancer treatment, highlighting partial understanding of HZ and RZV and a huge willingness to receive RZV from oncological staff. From June 2023 to April 2024, 220 pts received at least 1 dose of RZV, among which 152 (69%) received the second dose, resulting in a vaccination rate of 44% (220/496). Pts characteristics were as follows: 57% female, median age 70 (43-93) years, 80% ECOG PS 0-1, and 39% with at least 3 comorbidities. The most frequent tumors were breast 29%, lung 18%, colorectal 14%, prostate 10%, and upper GI 6%. The most common anticancer treatments were chemotherapy 44%, immunotherapy 28% targeted therapy 23%, and endocrine therapy 5%. No severe adverse event to RZV were reported. RZV was administered on average 7 (0-51) days before and 8 (0-70) days after intravenous therapy respectively.
Conclusions
Most cancer pts have a limited perception of the importance of vaccination. Vaccination with RZV was found to be safe. Our study highlights the potential for in-hospital vaccination strategies to enhance vaccination coverage and improve health outcomes among oncology pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
GSK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1481P - A case-control study of drug-eluting microspheres and blank microspheres in bronchial artery embolization for hemoptysis in non-small cell lung cancer
Presenter: Tongguo Si
Session: Poster session 10
1482P - Percutaneous transhepatic biliary drainage (PTBD) for palliation of jaundice in patients of unresectable/disseminated carcinoma gall bladder with hilar block: Is it a worthwhile enterprise?
Presenter: Saurabh Galodha
Session: Poster session 10
1484P - Inflammatory patterns of ascites in patients with solid tumors
Presenter: Julia Berger
Session: Poster session 10
1485P - Mitigating symptom clusters of patients with metastatic cancer through a remote physical exercise program (EXIO)
Presenter: Paulo Bergerot
Session: Poster session 10
1486P - A personalized rehabilitation pilot program for improving QOL of unresectable metastatic lung cancer patients
Presenter: Shani Shilo
Session: Poster session 10
1487P - Telemonitoring system effectiveness for alleviating cancer pain in patients with advanced cancer
Presenter: Shiori Yoshida
Session: Poster session 10
1488P - Use of mobile app “SUPPORT+” to enhance community palliative care in advanced cancer patients: A feasibility study
Presenter: Wendy Chan
Session: Poster session 10
1489P - Factors influencing adherence to electronic patient-reported outcomes in palliative cancer care
Presenter: Sarah Gomes
Session: Poster session 10
1490P - Health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain: A cross-sectional analytical study
Presenter: Herald Mapa
Session: Poster session 10
Resources:
Abstract